Harold Halman - Oncologix Tech President
| OCLG Stock | USD 0.0001 0.00 0.00% |
President
Mr. Harold Halman serves as Chief Operating Officer, Director of the Company. He was appointed as Chief Operating Officer and President of American Medical Products and Technologies, Inc., the subsiadiry of Oncologix Tech Inc., effective July 21, 2014 since 2016.
| Tenure | 8 years |
| Phone | 616-977-9933 |
| Web | https://www.oclghealth.com |
Oncologix Tech Management Efficiency
The company has return on total asset (ROA) of (0.1183) % which means that it has lost $0.1183 on every $100 spent on assets. This is way below average. Oncologix Tech's management efficiency ratios could be used to measure how well Oncologix Tech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Gregg Sutton | SurModics | 64 | |
| Hemanth CFA | Venus Concept | 48 | |
Management Performance
| Return On Asset | -0.12 |
Oncologix Tech Leadership Team
Elected by the shareholders, the Oncologix Tech's board of directors comprises two types of representatives: Oncologix Tech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncologix. The board's role is to monitor Oncologix Tech's management team and ensure that shareholders' interests are well served. Oncologix Tech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncologix Tech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harold Halman, President of The Medical Product and Technology Division and COO of The Medical Product and Technology Division | ||
| Michael Kramarz, CFO and Secretary | ||
| James Reed, Director Officer | ||
| Nikole Jessie, Director PR |
Oncologix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oncologix Tech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.12 | |||
| Profit Margin | (0.38) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 340.13 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 2.85 M | |||
| Gross Profit | 614.41 K | |||
| EBITDA | (572.25 K) |
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.